Off-target toxicity has killed off one of Bolt Biotherapeutics’ lead programs. Rather than push BDC-2034 into the clinic, the immuno-oncology startup is winding down spending on the anti-tumor ...
To some people, the phrase "custom bodywork" brings to mind images of gaudy overkill, such as Corvettes with 2-foot-wide fender flares or lowriders with more metalflake than pigment in the paint. But ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results